NPPA and Hypertension: This is particularly stimulating also taking into account that human recombinant ANP (Carperitide) has been already approved by the Ministry of Health and Welfare of Japan (Saito, 2010) as a drug for treatment of heart diseases/dysfunctions and hypertension, and, de facto, it has already passed the toxicological screening for the extension of the therapeutic application of this molecule.